620 related articles for article (PubMed ID: 27683798)
61. Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center.
Dragoni G; Bagnoli S; Le Grazie M; Campani C; Rogai F; Manetti N; Bensi C; Macrì G; Galli A; Milla M
J Dig Dis; 2019 May; 20(5):235-242. PubMed ID: 30927309
[TBL] [Abstract][Full Text] [Related]
62. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.
Shelton E; Allegretti JR; Stevens B; Lucci M; Khalili H; Nguyen DD; Sauk J; Giallourakis C; Garber J; Hamilton MJ; Tomczak M; Makrauer F; Burakoff RB; Levine J; de Silva P; Friedman S; Ananthakrishnan A; Korzenik JR; Yajnik V
Inflamm Bowel Dis; 2015 Dec; 21(12):2879-85. PubMed ID: 26288002
[TBL] [Abstract][Full Text] [Related]
63. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
[TBL] [Abstract][Full Text] [Related]
64. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
65. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
[TBL] [Abstract][Full Text] [Related]
66. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis.
Sandborn WJ; Colombel JF; Panaccione R; Dulai PS; Rosario M; Cao C; Barocas M; Lasch K
J Crohns Colitis; 2019 Feb; 13(2):172-181. PubMed ID: 30285104
[TBL] [Abstract][Full Text] [Related]
67. Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis.
Perry C; Fischer K; Elmoursi A; Kern C; Currier A; Kudaravalli P; Akanbi O; Tripathi N; Yarra P; Su L; Flomenhoft D; Stromberg A; Barrett TA
Dig Dis Sci; 2021 Jun; 66(6):2051-2058. PubMed ID: 32710192
[TBL] [Abstract][Full Text] [Related]
68. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
69. The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
Kassouri L; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
Dig Liver Dis; 2020 Oct; 52(10):1148-1155. PubMed ID: 32828693
[TBL] [Abstract][Full Text] [Related]
70. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.
Feagan BG; Schreiber S; Wolf DC; Axler JL; Kaviya A; James A; Curtis RI; Geransar P; Stallmach A; Ehehalt R; Bokemeyer B; Khalid JM; O'Byrne S
Inflamm Bowel Dis; 2019 May; 25(6):1028-1035. PubMed ID: 30365009
[TBL] [Abstract][Full Text] [Related]
71. Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.
Feagan BG; Bhayat F; Khalid M; Blake A; Travis SPL
J Crohns Colitis; 2018 Jul; 12(8):905-919. PubMed ID: 29788248
[TBL] [Abstract][Full Text] [Related]
72. Vedolizumab: first global approval.
Poole RM
Drugs; 2014 Jul; 74(11):1293-303. PubMed ID: 24985716
[TBL] [Abstract][Full Text] [Related]
73. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.
Osterman MT; Rosario M; Lasch K; Barocas M; Wilbur JD; Dirks NL; Gastonguay MR
Aliment Pharmacol Ther; 2019 Feb; 49(4):408-418. PubMed ID: 30663076
[TBL] [Abstract][Full Text] [Related]
74. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Scribano ML
World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
[TBL] [Abstract][Full Text] [Related]
75. Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study.
Attauabi M; Vind I; Pedersen G; Bendtsen F; Seidelin JB; Burisch J
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e709-e718. PubMed ID: 34101681
[TBL] [Abstract][Full Text] [Related]
76. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
Bohm M; Xu R; Zhang Y; Varma S; Fischer M; Kochhar G; Boland B; Singh S; Hirten R; Ungaro R; Shmidt E; Lasch K; Jairaith V; Hudesman D; Chang S; Lukin D; Swaminath A; Sands BE; Colombel JF; Kane S; Loftus EV; Shen B; Siegel CA; Sandborn WJ; Dulai PS;
Aliment Pharmacol Ther; 2020 Aug; 52(4):669-681. PubMed ID: 32656800
[TBL] [Abstract][Full Text] [Related]
77. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY.
Perin RL; Damião AOMC; Flores C; Ludvig JC; Magro DO; Miranda EF; Moraes AC; Nones RB; Teixeira FV; Zeroncio M; Kotze PG
Arq Gastroenterol; 2019; 56(3):312-317. PubMed ID: 31633731
[TBL] [Abstract][Full Text] [Related]
78. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
[TBL] [Abstract][Full Text] [Related]
79. Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Efken P; Mohl W; Hoffstadt M; Krause T; Schweitzer A; Schnoy E; Atreya R; Teich N; Trentmann L; Ehehalt R; Hartmann P; Schreiber S
Inflamm Bowel Dis; 2024 May; 30(5):746-756. PubMed ID: 37523666
[TBL] [Abstract][Full Text] [Related]
80. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]